Investors in Hyliion urged to seek lead plaintiff role in securities fraud lawsuit

Faruqi & Faruqi, LLP, a leading national securities law firm, is reminding investors who purchased Hyliion Holdings Corp. securities between May 12, 2026, and June 23, 2026, of an upcoming deadline to seek the role of lead plaintiff in a federal securities class action lawsuit.

The lawsuit, filed against Hyliion, alleges that the company and its executives engaged in securities fraud by making false and misleading statements about the company's business, operations, and prospects. Specifically, the complaint claims that Hyliion announced a deal with a recently formed entity without any apparent business operations, purportedly to artificially inflate the company's stock price. Additionally, it is alleged that certain individual defendants timed the announcement to coincide with insider trading activities.

On June 23, 2026, Pelican Way Research released a critical report, "Hyliion: A Glorified Science Project Who Has Continuously Failed to Meet Expectations and Is Now Throwing Around a Meaningless Deal," which contributed to a significant drop in Hyliion's stock price. The stock fell $1.27, or 17.2%, to close at $6.10 per share on that day.

Faruqi & Faruqi has a long history of representing investors in securities litigation, having recovered hundreds of millions of dollars for shareholders. The firm is now inviting eligible investors to review their trading records and contact the firm to discuss their legal rights and potential claims.

Any investor who purchased or otherwise acquired Hyliion securities on the New York Stock Exchange between May 12, 2026, and June 23, 2026, inclusive, may be eligible to participate in this lawsuit. Investors are not required to seek appointment as lead plaintiff to be considered a class member or to potentially share in any recovery that may be obtained.